El Warrak, Samantha
Kharfan-Dabaja, Mohamed A. http://orcid.org/0000-0001-7394-5185
Iqbal, Madiha http://orcid.org/0000-0001-6752-5440
Hamadani, Mehdi http://orcid.org/0000-0001-5372-510X
Chavez, Julio http://orcid.org/0000-0002-2045-6238
Mohty, Razan http://orcid.org/0000-0002-0189-8233
Article History
Received: 21 October 2023
Revised: 29 November 2023
Accepted: 1 December 2023
First Online: 16 December 2023
Competing interests
: RM, SEW, and MI have no COI to declare; MAK-D: Research/grant: Novartis, Bristol Myers Squibb and Pharmacyclics. MH: Research Support/Funding: ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, CRISPR, BMS, Kite. Abbvie, Caribou, Genmab. Speaker’s Bureau: ADC Therapeutics, AstraZeneca, BeiGene, Kite. DMC: Inc, Genentech, Myeloid Therapeutics, CRISPR; JC: Consulting: BMS, Kite/Gilead, Novartis, GenMab, Genentech, AstraZeneca, Janssen, AdiCet, Cellectis, BeiGene, ADC Therapeutics. Honoraria: Lilly, AstraZeneca, BeiGene. Research Support: Merck, Janssen, AstraZeneca, Adaptive